Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Despite significant advances in lung cancer research and novel therapies, a better understanding of the disease is crucially needed to facilitate early detection and appropriate diagnoses and to improve treatment outcomes. Extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, are released from all tested cell types and modulate cell-cell communication. EVs transfer a wide variety of molecules, such as proteins, messenger RNAs and microRNAs. Emerging data suggest that EVs play an important role in lung cancer pathogenesis and may have potential as biomarkers and therapeutics. Here, we review current research on EVs in lung cancer.
Keywords:
Biomarker; Exosome; Extracellular vesicle; Lung cancer; Microenvironment; Therapy.
Copyright © 2017 Elsevier Ltd. All rights reserved.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Biomarkers / metabolism
-
Cancer-Associated Fibroblasts / metabolism
-
Cancer-Associated Fibroblasts / pathology
-
Cell Communication
-
Drug Resistance, Neoplasm / genetics
-
Epithelial-Mesenchymal Transition / genetics
-
Extracellular Vesicles / metabolism*
-
Extracellular Vesicles / pathology
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology
-
Neoplasm Proteins / genetics*
-
Neoplasm Proteins / metabolism
-
Neovascularization, Pathologic / genetics
-
Neovascularization, Pathologic / metabolism*
-
Neovascularization, Pathologic / pathology
-
RNA, Neoplasm / genetics*
-
RNA, Neoplasm / metabolism
-
Signal Transduction
-
Translational Research, Biomedical / methods
-
Tumor Microenvironment / genetics
Substances
-
Antineoplastic Agents
-
Biomarkers
-
Neoplasm Proteins
-
RNA, Neoplasm